Inhibitors of immune checkpoint modulators and related methods
US10702526B2 · kind B2 · utility
2Cited by
6References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 15, 2016 |
| Grant date | Jul 7, 2020 |
| Priority date | — |
| Expiry date | Mar 30, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to the use MNK-specific inhibitors to inhibit immunosuppression components, such as immune checkpoint proteins PD-1, PD-L1, LAG3, and/or immunosuppressive cytokines, such as IL-10, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.